Perceptive Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Perceptive Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-238,000	Closed	-$1.12M	–	95
2024 Q4	$1.12M	Buy	+238,000	New	+$878K	0.03%	89
2022 Q4	–	Sell	-294,118	Closed	-$2.38M	–	102
2022 Q3	$2.38M	Hold	294,118	–	–	0.07%	101
2022 Q2	$1.44M	Hold	294,118	–	–	0.05%	98
2022 Q1	$6.96M	Hold	294,118	–	–	0.14%	93
2021 Q4	$5.2M	Hold	294,118	–	–	0.08%	117
2021 Q3	$8.3M	Hold	294,118	–	–	0.12%	109
2021 Q2	$3.08M	Buy	+294,118	New	+$2.97M	0.04%	133
2020 Q3	–	Sell	-894,118	Closed	-$15.8M	–	136
2020 Q2	$15.8M	Buy	894,118 +294,118	+49%	+$4.63M	0.26%	69
2020 Q1	$7.16M	Hold	600,000	–	–	0.19%	69
2019 Q4	$9.98M	Hold	600,000	–	–	0.2%	64
2019 Q3	$3.98M	Buy	+600,000	New	+$6.64M	0.11%	76

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's FULC Position: Q1 2025 in Review

Perceptive Advisors sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 238,000 shares — an estimated $1.12M sold.

Perceptive Advisors first reported a position in FULC in Q3 2019 and held it in 11 quarters. The position peaked at $15.8M in Q2 2020. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

Perceptive Advisors reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
Perceptive Advisors sold 238,000 Fulcrum Therapeutics shares in Q1 2025, an estimated $1.12M.
Perceptive Advisors first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 11 quarters.
Perceptive Advisors's Fulcrum Therapeutics position peaked at $15.8M in Q2 2020.
117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.